Dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD), although
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common
neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor …

Cognitive impairment occurs in most individuals with Parkinson's disease (PD), exacting a
high toll on patients, their caregivers, and the healthcare system. In this review, we begin by …

Finding useful biomarkers for Parkinson’s disease | Science Translational Medicine news
careers commentary Journals Science Science brought to you byGoogle Indexer Log in science …

The pathological hallmark of neurodegenerative diseases is the formation of toxic oligomers
by proteins such as alpha-synuclein (aSyn) or microtubule-associated protein tau (Tau) …

Most research on fluid biomarkers for central nervous system (CNS) disorders has so far
been performed using cerebrospinal fluid (CSF) as the biomarker source. CSF has the …

Introduction Cognitive dysfunction is among the most prevalent and debilitating non-motor
features of Parkinson's disease (PD). The neuropathological correlates of cognitive …

Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort
selection are an urgent need. While many promising markers have been discovered through …

Background Dementia is a syndrome that comprises many differing pathologies, including
Alzheimer's disease dementia (ADD), vascular dementia (VaD) and frontotemporal …

Background People with PD are at high risk of developing cognitive impairment and
dementia. Cross‐sectional studies have identified candidate biomarkers associated with …